Return to homepagePandemic Pact

Controlling the assembly of nanoparticles for RNA and protein encapsulation

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2022

  • Funder

    Carlsberg Foundation

  • Principal Investigator

    Jørgen Kjems

  • Research Location

    N/A

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Lipid nanoparticles (LNPs) was a key driver in the success of the mRNA COVID vaccines. They protected and helped the mRNA to cross our cell membrane to produce the SARS-CoV-2 protein. However, the LNPs used today are far from optimal and improvement is needed to avoid side effects and make the more effective at smaller dose. The project will use microfluidic to mix more biocompatible and homogenous LNPs with improved properties. This will also pave the way for much wider applications of mRNA medicine targeted to other organs and tissues.